HLB bioStep KRX:278650KOSDAQ
HLB바이오스텝 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days0
DART filings, 7 days0
Articles tracked11since Sep 11
In Q2 2026, HLB bioStep reported revenue of ₩16.0bn, down 10.2% year on year, and an operating loss of ₩1.9bn. HLB bioStep (HLB바이오스텝) appeared in 0 Korean news articles and 0 DART filings over the past seven days. Coverage peaked on Oct 19 with 1 article.
HLB bioStep quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩16.0bn | -10.2% | −₩1.9bn margin −11.9% | −₩3.5bn |
| Q1 2026 | ₩13.5bn | -0.7% | −₩2.6bn margin −19.4% | −₩2.1bn |
| Q4 2025 derived | ₩18.7bn | +16.0% | −₩2.2bn margin −11.8% | −₩14.5bn |
| Q3 2025 | ₩24.0bn | +29.3% | ₩455m margin 1.9% | ₩770m |
| Q2 2025 | ₩17.8bn | +49.0% | −₩4.3bn margin −24.2% | −₩4.6bn |
| Q1 2025 | ₩13.6bn | +17.4% | −₩2.5bn margin −18.8% | −₩1.8bn |
| Q4 2024 derived | ₩16.1bn | +9.6% | −₩4.7bn margin −29.0% | −₩3.4bn |
| Q3 2024 | ₩18.5bn | +69.3% | −₩2.7bn margin −14.4% | −₩830m |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
HLB bioStep top stories 2 weeks, by number of outlets
- 1
Latest HLB bioStep news Korean headlines
-
MajorFeatured[ET특징주] HLB, 간암 신약 제조시설 FDA 실사 종결… HLB바이오스텝 上
7 more on this story · 7 outlets
- HLB 간암신약, 완제 제조시설 FDA 실사 'VAI' 종결메디파나뉴스 · Oct 6 09:01
- HLB, 리보세라닙 제조시설 FDA 실사 ‘VAI’ 종결…간암 신약 재신청 준비이투데이 · Oct 6 09:12
- HLB 간암신약 재도전 속도⋯완제시설 FDA 실사 'VAI' 종결아이뉴스24 · Oct 6 09:56
- HLB 간암신약 제조시설 FDA 실사 VAI…NDA 재제출 속도뉴스1 · Oct 6 10:22
- HLB, 간암 신약 제조시설 FDA 실사 VAI 종결중소기업신문 · Oct 6 15:19
- 리보세라닙 제조시설 FDA 실사 VAI 종결, HLB 허가 재신청 속도약사공론 · Oct 6 17:54
- HLB, 리보세라닙 제조시설 FDA 실사 ‘VAI’ 종결…"NDA 재제출 추진"한국일보 · Oct 6 20:35